Editor's Note: At the 2026 European Society for Medical Oncology (ESMO) Congress, the Department of Urology at West China Hospital of Sichuan University reported interim results from the WUTSUP-02 study, which explored the value of neoadjuvant treatment with disitamab vedotin plus tislelizumab, followed by surgery and adjuvant tislelizumab, in patients with high-risk upper tract urothelial carcinoma (UTUC). Addressing the limited perioperative treatment options for this patient population, Professor Yige Bao of West China Hospital of Sichuan University discusses the rationale behind the WUTSUP-02 study, its interim efficacy findings, and future directions for patient selection and evidence generation.

Clinical Need: Seeking Perioperative Treatment Options Beyond Chemotherapy

Oncology Frontier – UroStream: What are the main challenges in perioperative treatment for patients with high-risk upper tract urothelial carcinoma? How did these unmet clinical needs lead to the development of the WUTSUP-02 study?

Professor Yige Bao West China Hospital of Sichuan University

Compared with bladder cancer, upper tract urothelial carcinoma (UTUC) often has a more insidious onset, and many patients are already diagnosed at the invasive or locally advanced stage. Even after radical surgery, these patients remain at considerable risk of recurrence. Therefore, perioperative treatments, including neoadjuvant and adjuvant therapy, are particularly important.

However, clinical evidence supporting perioperative treatment for UTUC remains relatively limited. For eligible patients, adjuvant chemotherapy following radical surgery is an important evidence-based treatment strategy, supported by the POUT study. One major clinical challenge is that radical nephroureterectomy requires removal of one kidney, while chemotherapy also has specific renal function requirements. Some patients who would otherwise be candidates for postoperative adjuvant chemotherapy may lose this treatment opportunity because of declining renal function after surgery, further limiting their subsequent treatment options.

We therefore urgently need to explore perioperative treatment strategies beyond chemotherapy for patients with high-risk UTUC. In recent years, novel agents, particularly antibody-drug conjugates (ADCs) and immunotherapies, have driven advances in bladder cancer treatment. Since UTUC is also a type of urothelial carcinoma, can these therapies bring similar progress to this disease? The combination of disitamab vedotin, a domestically developed ADC, with immunotherapy is precisely one of the approaches we hope to investigate further.

Study Design: Integrating Neoadjuvant Treatment, Surgery, and Postoperative Adjuvant Therapy

Oncology Frontier – UroStream: What was the rationale behind the WUTSUP-02 study design? Could you introduce the study population, treatment sequence, and primary evaluation endpoints?

Professor Yige Bao: In response to the clinical needs described above, our research team initiated the investigator-initiated WUTSUP-02 clinical study. WUTSUP is the collective name for a series of studies on perioperative systemic treatment for UTUC initiated by West China Hospital of Sichuan University. WUTSUP-02 focuses on a neoadjuvant treatment regimen combining disitamab vedotin and tislelizumab.

The study enrolled patients with histologically confirmed high-risk or locally advanced UTUC who were eligible for radical surgery, with clinical stages ranging from T2 to T4 and N0 to N2. Following tissue biopsy, all patients underwent testing for human epidermal growth factor receptor 2 (HER2) expression. The study cohort included patients with HER2 immunohistochemistry (IHC) scores of 1+ to 3+, including those with HER2-low expression.

The treatment regimen consisted of four cycles of neoadjuvant disitamab vedotin plus tislelizumab before surgery. Patients then underwent radical surgical resection, followed by adjuvant tislelizumab. Pathological complete response (pCR) was designated as the primary efficacy endpoint. Secondary endpoints included metastasis-free survival, objective response rate, overall survival, and the incidence of adverse events. The study aims to systematically evaluate the clinical value of this perioperative treatment strategy across multiple dimensions, including pathological response, long-term antitumor efficacy, and treatment safety.

Interim Results: Pathological Responses and Survival Findings Provide Encouraging Signals

Oncology Frontier – UroStream: What are the key findings from the interim results presented at this year’s congress? How should we interpret the pathological response and survival signals?

Professor Yige Bao: Based on the current interim follow-up data, the pCR rate was approximately 28% among patients who had completed surgery and met the criteria for efficacy evaluation. Given that this study also included patients with low HER2 expression (IHC 1+), this response rate is of considerable clinical relevance. Previous studies of neoadjuvant chemotherapy have generally reported pCR rates of approximately 10%–20%, providing a reference point for interpreting the current findings. However, the relative benefit of this treatment regimen compared with existing standard treatments still requires validation in larger studies.

Under this comprehensive treatment model, which incorporates neoadjuvant therapy, radical surgery, and postoperative adjuvant treatment, the 2-year overall survival rate among patients was approximately 87%. The pathological response and survival benefit signals observed at this stage provide encouraging clinical evidence to support further investigation of this treatment strategy.

Future Directions: Identifying the Patients Most Likely to Benefit and Defining the Role of Treatment

Oncology Frontier – UroStream: What are the current limitations of the study? Which key questions need to be addressed in future research to identify the patients most likely to benefit and clarify the role of this treatment strategy?

Professor Yige Bao: The findings reported in this study are based on an interim analysis and do not represent the final results. WUTSUP-02 is a single-arm clinical study with a relatively limited sample size. The future clinical value of neoadjuvant therapy based on HER2-targeted ADCs, as well as its role within the perioperative treatment framework, still needs to be clarified.

One central question is which patient population is best suited to this treatment strategy. Do patients with HER2 IHC 2+ or 3+ expression achieve better treatment outcomes than those with IHC 1+ expression? These questions require further analysis after patient enrollment is completed and more comprehensive follow-up data have been accumulated. They will also need to be validated in larger, higher-quality clinical studies.

Going forward, our research team will continue to advance the ongoing study with a focus on quality and rigor, while assessing the feasibility of conducting larger-scale studies based on the findings obtained at each stage. Based on the current observations, the combination of HER2-targeted ADCs and immune checkpoint inhibitors offers a new research direction for exploring perioperative treatment options beyond chemotherapy in patients with UTUC. The optimal patient population and the clinical value of this approach remain to be clarified through further research.

Conclusion

The WUTSUP-02 study addresses the limited perioperative treatment options available to patients with high-risk UTUC by exploring an ADC-based combination with immunotherapy as neoadjuvant treatment, followed by surgery and postoperative adjuvant therapy. The current interim findings reveal encouraging signals in terms of pathological response and survival, although the study remains at an exploratory stage, with a small sample size and a single-arm design. As enrollment and follow-up continue, clarifying differences in treatment benefit across HER2 expression subgroups, identifying the most appropriate patient population, and defining the role of this strategy will be essential to its further development.

Professor Yige Bao